Class aan daroogada cusub ee JYMed ayaa sameeyey horumar la taaban karo, Laipushutai ayaa la filayaa in ay noqdaan safka ugu horreeya ee daroogada UC.

On June 29, 2017, horumarinta Laipushutai, fasalka aan daawada cusub horumarinta iskaashiga ee JYMed iyo Guangzhou Linkhealth Medical Technology Co., Ltd., uu sameeyay horumar la taaban karo. dhawaaqo IND daroogada ee la aqbalay by CFDA ah.

JYMed iyo Guangzhou Linkhealth Medical Technology Co., Ltd. gaaray heshiis iskaashi ah ee 2016-ka in ay si wadajir ah loo horumariyo wax soo saarka this ee Shiinaha. noocyada ayaa dhameystirtay POC waxbarashada clinical ee Midowga Yurub oo gaaray heerka ammaanka iyo dembidhaafka wanaagsan. Labada FDA iyo EMA ku aqoonsadaan in noocyada this waxaa laga dalban karaa daaweynta on line aan / II, iyo mudnaan la siin doonaa, si ay gargaar iyo daaweynta bukaannada qaba ulcerös kolit dhexdhexaad ah in dabagal tijaabo ah CFDA.

colitis Ulcerative (UC) waa, cudur joogto ah non-gaar ah bararka in dhacdaa malawadka iyo xiidanka. Sida laga soo xigtay tirakoob, heerka dhacdooyinka ee UC waa 1.2 ilaa 20.3 kiisaska / 100,000 qof sannad kasta iyo baahsanaanta ee UC waa 7.6 in 246,0 kiisaska / 10,000 oo qof sanadkiiba. dhacdooyinka ee UC badan yahay in dhalinyarada waaweyn. suuqa UC uu leeyahay ballaaran iyo dalabka daroogooyinka, iyo sii wadi doonaan si ay u ilaaliyaan isbedel ah koritaanka sare ee mustaqbalka. Ilaa hadda, daroogada UC-line koowaad waxaa inta badan ku salaysan mesalazine iyo hormoonnada, iyo daawooyinka raaca labaad waxaa ka mid ah immunosuppressants iyo antibodies monoclonal noolaha. Mesalazine leedahay mugga iibka 1 billion ee Shiinaha iyo US $ 2 billion oo dalka Mareykanka ah ee 2015. Laipushutai ayaa jawaab ka wanaagsan in calaamadaha UC, waana mid ka ammaan badan daawooyinka raaca koowaad ee hadda. Waxay leedahay a faa'iido suuqa wanaagsan, waxaana la filayaa in ay noqon a-line ugu horeysay UC daroogada.